Biomed Central Ltd

SHERPA: Unknown

People

  1. Vickers
    Vickers
  2. Postow
    Postow
  3. D'Angelo
    D'Angelo
  4. Offit
    Offit
  5. Budhu
    Budhu
  6. Motzer
    Motzer
  7. Cheung
    Cheung
  8. Voss
    Voss
  9. O'Reilly
    O'Reilly
  10. Robson
    Robson

Groups

  1. Department of Medicine (556)
  2. Solid Tumor Oncology Division (454)
  3. GSK Faculty (290)
  4. Sloan Kettering Institute Postdocs (193)
  5. Population Sciences Research Program (158)
  6. Hematologic Malignancies, Division of (152)
  7. Epidemiology and Biostatistics (151)
  8. Melanoma and Immunotherapeutics Service (148)
  9. Survivorship Research (121)
  10. Surgery (118)
Search Within
Formats
  1. Journal Article (745)
  2. Meeting Abstract (257)
  3. Review (40)
  4. Guidelines (20)
  5. Editorial (10)
  6. Research Letter (7)
  7. Correspondence (4)
  8. Conference Paper (1)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (556)
  2. Solid Tumor Oncology Division (454)
  3. GSK Faculty (290)
  4. Sloan Kettering Institute Postdocs (193)
  5. Population Sciences Research Program (158)
  6. Hematologic Malignancies, Division of (152)

More Groups

People
  1. Jedd Wolchok (83)
  2. Taha Merghoub (55)
  3. Andrew Vickers (44)
  4. Michael Postow (43)
  5. Matthew Hellmann (30)
  6. Roberta Zappasodi (24)

More People

Years
  1. 2025 (28)
  2. 2024 (63)
  3. 2023 (45)
  4. 2022 (123)
  5. 2021 (91)
  6. 2020 (99)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (404)
  2. Breast Cancer Research (67)
  3. BMC Cancer (64)
  4. Genome Biology (46)
  5. Journal of Hematology & Oncology (42)
  6. Journal of Translational Medicine (35)

More Publications

Results (1085)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II study of nivolumab, ipilimumab, plus androgen receptor blockade with bicalutamide to enhance thymic T-Cell production and immunotherapy response in metastatic breast cancer
    Meeting Abstract

    Page, D.; Collins, K.; Chun, B.; Sun, Z.; Koguchi, Y.; Redmond, W.; Martel, M.; Wu, Y.; Moxon, N.; Mellinger, S.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Biomarker correlates of response in patients with advanced myxoid/round cell liposarcoma (MRCLS) treated with NY-ESO-1 TCR T Cells (letetresgene autoleucel)
    Meeting Abstract

    Kapoor, G.; Zajic, S.; Suchindran, S.; Kim, J.; Eleftheriadou, I.; Huff, A.; Nathenson, M.; Druta, M.; Van Tine, B.; Somaiah, N.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Multiomic biomarker signatures identify subsets of patients who may benefit from either nivolumab or sotigalimab in combination with chemotherapy in metastatic pancreatic cancer
    Meeting Abstract

    Maurer, D.; Yu, J. X.; Sklodowski, K.; Tognetti, M.; Reiter, L.; Bruderer, R.; Vowinckel, J.; Pfeiffer, S.; O'Hara, M.; O'Reilly, E.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • T cell intrinsic DNA damage and repair response as a novel marker associated with clinical response to PD-1 blockade
    Meeting Abstract

    Muroyama, Y.; Manne, S.; Greenplate, A.; Mathew, D.; Oldridge, D.; Chilukuri, L.; Xu, C.; Herati, R.; Huang, A.; Zamarin, D.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Development and validation of a neoantigen-specific T cell gene signature to identify antitumor T cells in lung cancer and melanoma
    Meeting Abstract

    Zhang, J.; Caushi, J.; Oliveira, G.; Zhang, B.; Ji, Z.; Naidoo, J.; Marrone, K.; Taube, J.; Hellmann, M.; Brahmer, J.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial
    Meeting Abstract

    Feils, A.; Erbe, A.; Birstler, J.; Kim, K.; Hoch, U.; Currie, S.; Nguyen, T.; Yu, D.; Siefker-Radtke, A.; Tannir, N.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • T cell immunotherapies trigger neutrophil activation to eliminate tumor antigen escape variants
    Meeting Abstract

    Hirschhorn, D.; Budhu, S.; Schröder, D.; Kraehenbuehl, L.; Flammar, A. L.; Chow, A.; Schulze, I.; Schad, S.; Ricca, J.; Gasmi, B.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • HLA-independent T cell receptors effectively target low abundance antigens
    Meeting Abstract

    Mansilla-Soto, J.; Eyquem, J.; Haubner, S.; Hamieh, M.; Feucht, J.; Paillon, N.; Zucchetti, A.; Li, Z.; Sjöstrand, M.; Lindenbergh, P.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • In silico modeling of combination systemic therapy for advanced renal cell carcinoma
    Journal Article

    Kotecha, R. R.; Hsu, D. J.; Lee, C. H.; Patil, S.; Voss, M. H.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • A method for in vivo treatment verification of IMRT and VMAT based on electronic portal imaging device
    Journal Article

    Zhang, J.; Li, X.; Lu, M.; Zhang, Q.; Zhang, X.; Yang, R.; Chan, M. F.; Wen, J.
    Radiation Oncology (2021)

    Fulltext@MSK | Save